PUBLISHER: The Business Research Company | PRODUCT CODE: 1889362
PUBLISHER: The Business Research Company | PRODUCT CODE: 1889362
A direct coombs test (DCT) antibody is an antibody that targets the dopachrome tautomerase (DCT) protein, also known as tyrosinase related protein 2 (TRP 2). This protein plays an important role in melanin biosynthesis and is commonly used as a marker for melanocyte differentiation and melanoma research. It is widely used to detect, measure, and study DCT expression in biological samples.
The main types of direct coombs test (DCT) antibody include monoclonal antibodies, polyclonal antibodies, recombinant antibodies, and bispecific antibodies. Monoclonal antibodies are laboratory produced molecules created to bind specifically to antigens on red blood cells, allowing accurate detection of immune mediated hemolysis during diagnostic testing. The various sources include human, mouse, rabbit, other mammals, and recombinant sources and are used across applications such as cancer treatment, autoimmune diseases, infectious diseases, transplant rejection, and other related uses. The key end users include pharmaceutical companies, biotechnology firms, contract research organizations (CROs), academic and research institutes, and diagnostic laboratories.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.
The direct coombs test (DCT) antibody market research report is one of a series of new reports from The Business Research Company that provides direct coombs test (DCT) antibody market statistics, including direct coombs test (DCT) antibody industry global market size, regional shares, competitors with a direct coombs test (DCT) antibody market share, detailed direct coombs test (DCT) antibody market segments, market trends and opportunities, and any further data you may need to thrive in the direct coombs test (DCT) antibody industry. This direct coombs test (DCT) antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The direct coombs test (DCT) antibody market size has grown rapidly in recent years. It will grow from $5.87 billion in 2024 to $6.55 billion in 2025 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to rising prevalence of hemolytic disease of the newborn, increasing autoimmune hemolytic anemia diagnoses, growing blood transfusion procedures, expanding hospital blood bank capacity, and rising antenatal screening programs.
The direct coombs test (DCT) antibody market size is expected to see rapid growth in the next few years. It will grow to $10.06 billion in 2029 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to a growing geriatric population, rising oncology and hematology treatment volumes, expanding private diagnostic laboratory networks, growing demand for universal blood typing and cross matching, and increasing screening for hemolytic transfusion reactions. Major trends in the forecast period include integration of polymerase chain reaction based blood group genotyping with serology workflows, artificial intelligence assisted quality control and lot release analytics, Internet of Things enabled cold chain monitoring and traceability, adoption of cloud based laboratory information management systems, and advances in lyophilization and stabilizer chemistry for extended shelf life.
The rising demand for personalized medicine is expected to propel the growth of the direct coombs test DCT antibody market going forward. Personalized medicine is a medical approach that involves tailoring treatments to individual patients based on their genetic, environmental, and lifestyle factors to optimize outcomes and improve care. The demand for personalized medicine is increasing due to advancements in genomic technologies, which enable the precise identification of genetic variations and tailored treatments for individuals. Direct coombs test DCT antibody supports personalized medicine by enabling precise detection of antibodies or complement bound to red blood cells. It helps identify immune mediated hemolytic conditions, allowing clinicians to tailor treatments based on a patient's specific immune profile, improving diagnostic accuracy and therapeutic outcomes. For instance, in February 2024, according to the Personalized Medicine Coalition PMC, a US based nonprofit organization, the United States Food and Drug Administration approved twenty six new personalized medicines in 2023, a significant increase from the twelve approved in 2022. Therefore, the rising demand for personalized medicine is driving the growth of the direct coombs test DCT antibody market.
Major companies operating in the direct coombs test DCT antibody market are focusing on developing technologically advanced solutions such as gel based immunoassays to ensure reliability, enhance laboratory workflow, and maintain high standards in pre transfusion testing. Gel based immunoassays refer to a type of laboratory test in which antibodies and antigens interact within a gel matrix, allowing for visual detection of reactions such as agglutination. For instance, in October 2025, QuidelOrtho Corporation, a US based in vitro diagnostics company, received Food and Drug Administration clearance for MTS DAT Card for gel based direct antiglobulin testing on the ORTHO VISION platform. It features a ready to use card containing anti IgG and anti C3d monospecific reagents in the gel matrix of separate microtubes. This design allows for clear, objective, and simultaneous differentiation between IgG and complement sensitization, streamlining the investigation of immune mediated hemolytic anemias and hemolytic disease of the fetus and newborn. Its core purpose is to detect immunoglobulin G or complement bound to red blood cells, supporting hemolysis investigation and enhancing transfusion safety.
In March 2023, Werfen Life Sciences SA, a Spain based in vitro diagnostics company, acquired Immucor Inc. for approximately two point zero billion dollars. With this acquisition, Werfen aims to strengthen its leadership in transfusion medicine by integrating Immucor's immunohematology portfolio, enhancing automation, expanding global reach, and improving patient safety in hemolysis detection and transfusion management. Immucor Inc. is a US based company specializing in direct coombs test DCT antibody and immunohematology diagnostics.
Major companies operating in the direct coombs test (dct) antibody market are Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bio-Rad Laboratories Inc., Fortress Diagnostics Limited, Lab-Care Diagnostics (India) Pvt. Ltd., SIFIN Diagnostics GmbH, Hemo Bioscience Inc., Rapid Labs Ltd, AnaMol Laboratories Pvt. Ltd., Jiangyin Libo Biotechnology Co. Ltd., MicroSidd India Pvt. Ltd., Atlas Medical GmbH, Lorne Laboratories Ltd, Sanquin Reagents B.V., BAG Diagnostics GmbH, CE-Immundiagnostika GmbH, Biolab Diagnostics (India) Pvt. Ltd., Singapore Biosciences Pte. Ltd.
North America was the largest region in the direct coombs test (DCT) antibody market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in direct coombs test (DCT) antibody report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the direct coombs test (DCT) antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The direct coombs test (DCT) antibody consists of sales of primary antibodies, secondary antibodies, antibody kits, assay reagents, western blot reagents, enzyme-linked immunosorbent assay (ELISA) kits, immunohistochemistry kits, ready-to-use detection kit, anti- direct coombs test (DCT) (TRP-2), and rabbit monoclonal primary antibody. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Direct Coombs Test (DCT) Antibody Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on direct coombs test (dct) antibody market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for direct coombs test (dct) antibody ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The direct coombs test (dct) antibody market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.